A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentations have concluded.
Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...
The addition of AK104 to concurrent chemoradiotherapy improved survival outcomes for patients with locally advanced cervical ...
Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...
Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...
A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...
The pathologic tumor response (pTR) rate increased from 41.6% with single-agent nivolumab (Opdivo) to 63.6% with nivolumab plus the CTLA-4 inhibitor ipilimumab (Yervoy) and 73.3% with nivolumab ...
(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...
Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback